DarioHealth Showcases 14.3% Weight Loss and $5,077 Estimated Savings at ADA Sessions
DRIO•DarioHealth presented four ADA studies showing 6.4% weight loss at 12 months standalone and 14.3% when paired with GLP-1, with 44.8% of high-risk users achieving at least 1% eA1c reduction. Participants also saw 0.23 fewer hospitalizations per patient per year, implying about $5,077 in payer savings each.
1. Study Presentations and Scope
DarioHealth presented four new studies at the American Diabetes Association Scientific Sessions, adding to a body of 27 studies over eight years. These findings emphasize the platform’s sustained engagement benefits across high-risk diabetes, hypertension and obesity populations, targeting payers, employers and enterprise buyers.
2. Clinical Outcomes and Cost Savings
The digital health intervention delivered 6.4% weight loss at 12 months alone and 14.3% when combined with GLP-1 therapy, exceeding pharmacotherapy-only benchmarks. High-risk users achieved at least a 1% eA1c reduction in 44.8% of cases, while participants experienced 0.23 fewer hospitalizations per patient per year, translating to approximately $5,077 in annual payer savings per participant.
3. Strategic Shift to Enterprise Revenue
The studies reinforce DarioHealth’s shift toward claims-based and outcomes-driven payment models, positioning the company to partner with health plans, self-insured employers and other enterprise buyers. Its AI-driven engagement engine, connected devices and personalized coaching support an integrated cardiometabolic platform designed to reduce care complexity and costs across overlapping chronic conditions.
